Price
$0.00001
Increased by 0.00%
Dollar Volume
N/A
ADR%
NaN
Market Cap.
0.00
Shares Float
0.00
Shares Outstanding
0.00
Beta
0.00
Price / Earnings
0.00
BPR
N/A
20D Range
N/A N/A
50D Range
N/A N/A
200D Range
N/A N/A
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Jun 30, 22 0.00 - -539.76 K -
Decreased by N/A%
-
Mar 31, 22 0.00 - -500.22 K -
Decreased by N/A%
-
Jun 30, 21 0.00 - -47.82 K -
Decreased by N/A%
-
Mar 31, 21 0.00 - -47.97 K -
Decreased by N/A%
-
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Alopexx, Inc., a clinical stage biotechnology company, focusing on developing novel immune therapeutics for the prevention, treatment, and mitigation of bacterial, fungal, and parasitic infections. Its lead products include Vaccine AV0328, a synthetic poly N-acetyl glucosamine (PNAG) vaccine that has completed Phase I first-in-man trial for the treatment of streptococcus pneumoniae, meningococcal infections, Alzheimer's disease, and type 1 diabetes mellitus; and F598, a monoclonal antibody that has completed Phase I and pilot Phase II trials for preventing and ameliorating gram-negative and gram-positive bacterial infections along with fungal infections by organisms that express PNAG in patients admitted to intensive care units. The company is headquartered in Cambridge, Massachusetts.